Tetherex Pharmaceuticals

Tetherex Pharmaceuticals is a clinical-stage drug development company based in the United States. Founded in 2014 as a spin-off of Selexys Pharmaceuticals, Tetherex is committed to advancing the understanding of inflammation and developing novel treatments for inflammatory diseases, infectious diseases, and cancer. The company's lead program focuses on a functionally blocking anti-PSGL-1 antibody for the treatment of asthma and chronic obstructive pulmonary disease.